Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Maribavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Takeda Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results of the SOLSTICE trial are promising and show that maribavir may help with post-transplant CMV viremia, including cases of drug-resistance for which there is an unmet need.
Brand Name : SHP620
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 21, 2021
Lead Product(s) : Maribavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Takeda Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?